Opiant Pharmaceuticals to Hold Virtual 2022 Annual Meeting of Shareholders on Tuesday, June 14… | Your money

SANTA MONICA, Calif., May 20, 2022 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), today announced that to protect the health and safety of its shareholders, employees and communities Amid a local increase in COVID-19, Opiant’s 2022 Annual Meeting of Shareholders will be held in a virtual-only meeting format via live audio webcast. The meeting will be held online only and will begin at 9:00 a.m. PDT on June 14, 2022, as previously scheduled. Matters to be voted on at the 2022 annual meeting remain unchanged.

The Company’s proxy statement setting out the formal business to be conducted at the Meeting is available in the Investors section of the Company’s website at:


Shareholders who choose to attend the meeting virtually can do so as follows:

Date: Tuesday, June 14, 2022 Time: 9:00 a.m. (PDT) Live Virtual Meeting: https://zoom.us/j/95041888598 (Meeting number: 950 4188 8598)

Find your local number via https://zoom.us/u/apRdfUhqI

Shareholders of record as of the close of business on April 18, 2021, the record date for the 2022 Annual Meeting, are eligible to participate in the virtual meeting and will need their 16-digit control number to vote electronically at of the virtual meeting by sending an e-mail to: [email protected]

Important Information for Voting Shares

Your vote is important. Whether or not shareholders plan to attend the virtual-only annual meeting, Opiant urges shareholders to vote and submit their proxies prior to the meeting through one of the methods described in the proxy materials.

Registered shareholders with internet access may submit proxies until 11:59 p.m. Eastern Time on June 14, 2022, by following the instructions on your proxy cards or at www.voteproxy.com.

Shareholders who have already voted for their shares do not need to vote again due to this change in meeting format.

A list of shareholders eligible to vote at the 2022 annual meeting will be available for review by interested shareholders. Please contact the Company’s Investor Relations by emailing [email protected]if you wish to consult the list before the meeting.

Attend the annual meeting as a guest

Those without a control number can attend the virtual meeting as guests, but will not be able to vote.

About Opiant Pharmaceuticals, Inc. Opiant Pharmaceuticals, Inc., the company that developed NARCAN® nasal spray, is building a leading franchise of new addiction and overdose medications. For more information visit: www.opiant.com.

Investor Relations Contacts:

Ben Atkins Vice President of Corporate Communications and Investor Relations [email protected] (310) 598-5410

Copyright 2022 GlobeNewswire, Inc.

Comments are closed.